Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
The stock's long-term returns remain a key discussion point for holders. See our latest analysis for Takeda Pharmaceutical. Takeda Pharmaceutical's shares have edged lower in recent weeks, but zooming out shows a steady climb. The company delivered a 3.6% total shareholder return over the last year and an impressive 45.6% over five years. The latest moves seem to reflect both cautious optimism about sector growth and some recalibration of risk after a solid multi-year run. If you're interested in discovering more movers in the healthcare space, simply check out our picks via the See the full list for free. With shares trading below analyst price targets and the company posting steady earnings growth, the question is whether Takeda Pharmaceutical offers investors an undervalued entry point or if the market has already factored in future gains. Most Popular Narrative: 14.8% Undervalued Topping the chart of valuation views, the most closely followed narrative sets Takeda Phar
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.MarketBeat
- Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]Yahoo! Finance
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)Business Wire
- Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]Yahoo! Finance
- Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 12/18/25 - Form 6-K
- 12/9/25 - Form 144
- 12/8/25 - Form 6-K
- TAK's page on the SEC website